Advertisement
Advertise on MSK
Musculoskeletal Report
January 04, 2011
MSK Report Video Podcasts

Meeting Highlights

ISEMIR 2009: Video coverage of the Meeting
Miami, March 27, 2009
RWCS 2009: Video coverage of the Symposium
Maui, January 14-17, 2009
ACR 2008: News from the Annual Scientific Meeting
San Francisco, October 24-29, 2008
EULAR 2008: Coverage of the Congress
Paris, June 11-14, 2008
ISEMIR 2008: Video coverage of the Meeting
Chicago, April 10, 2008
AAOS 2008: News from the Annual Meeting
San Francisco, March 5-9, 2008

Affiliations

Arthritis Research
Lupus Research Institute - Letting Science Lead the Way to a Cure
RSS Feeds

Maxime Dougados, MD

Maxime Dougados, MD
Professor of Rheumatology, Rene Descartes University
Department of Rheumatology B, Cochin Hospital
Paris, France


Maxime Dougados, MD, is Professor of Rheumatology at René Descartes University in Paris, France, and Chief of the Department of Rheumatology at Cochin Hospital, also in Paris. He is a long-time member of the Societé Française de Rhumatologie, the American College of Rheumatology, and the Osteoarthritis Research Society. Dr. Dougados serves as Chairman of the European League Against Rheumatism (EULAR) Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) and as Vice President of Assessment of Ankylosing Spondylitis (ASAS).


Dr. Dougados' research focuses principally on outcome measures in rheumatic diseases, including osteoarthritis, bone diseases, and inflammatory rheumatic disease, and on classification criteria and prognostic factors of rheumatic diseases. He has acted as the advisory editor of prestigious scientific journals including Clinical Experimental Rheumatology, Revue du Rhumatisme, The British Journal of Rheumatology, and Arthritis and Rheumatism. Recent journal publications by Dr. Dougados include "Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria," published in The Journal of Rheumatology, and ?Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five years follow-up of a prospective double blind controlled study, in Annals of the Rheumatic Diseases.